Monday, December 23, 2024
HomeTagsLong-Term

Long-Term

New Amgen Data at Esc 2022 Show Long-Term LDL-C Lowering With Repatha Was Well-Tolerated

Amgen presented new compelling data from the Phase 3 FOURIER open label extension (OLE) studies of Repatha (evolocumab) in adults with atherosclerotic cardiovascular disease...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics